Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties at subanaesthetic doses, thus providing a valuable research tool for the investigation of the neurobiology of major depressive disorder (MDD). This multimodal imaging study in 14 healthy subjects reveals the neuropharmacological effects of a single intravenous subanaesthetic ketamine infusion on fMRI-BOLD responses during an emotional processing task and their relationship to glutamatergic metabolite concentrations in the pregenual anterior cingulate cortex (PACC) assessed by proton magnetic resonance spectroscopy (1H-MRS) and indicates a close relationship between BOLD reactivity and glutamatergic metabolism after pharmacological stimulation
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Background: Using proton magnetic resonance spectroscopy (1H-MRS) an increase in glutamatergic metab...
In this multimodal, double-blind, randomized, placebo-controlled PET-MRS study in 20 healthy subject...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties at ...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties, th...
Background / Purpose: Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidep...
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at su...
Background: An urgent need exists for faster-acting pharmacological treatments in major depressive d...
Objective Based on the growing evidence for imbalance with regard to glutamatergic (Glu) neurotransm...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties at ...
Background / Purpose: Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidep...
Increased amygdala reactivity might lead to negative bias during emotional processing that can be re...
Many neuroimaging findings are compatible with the hypothesis that limbic hyperactivity during evalu...
Objective Using proton magnetic resonance spectroscopy (1H-MRS) an increase in glutamatergic metabol...
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Background: Using proton magnetic resonance spectroscopy (1H-MRS) an increase in glutamatergic metab...
In this multimodal, double-blind, randomized, placebo-controlled PET-MRS study in 20 healthy subject...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties at ...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties, th...
Background / Purpose: Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidep...
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at su...
Background: An urgent need exists for faster-acting pharmacological treatments in major depressive d...
Objective Based on the growing evidence for imbalance with regard to glutamatergic (Glu) neurotransm...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties at ...
Background / Purpose: Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidep...
Increased amygdala reactivity might lead to negative bias during emotional processing that can be re...
Many neuroimaging findings are compatible with the hypothesis that limbic hyperactivity during evalu...
Objective Using proton magnetic resonance spectroscopy (1H-MRS) an increase in glutamatergic metabol...
Ketamine is a powerful glutamatergic long-lasting antidepressant, efficient in intractable major dep...
Background: Using proton magnetic resonance spectroscopy (1H-MRS) an increase in glutamatergic metab...
In this multimodal, double-blind, randomized, placebo-controlled PET-MRS study in 20 healthy subject...